Clinical Trial News and Research

RSS

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.

18 Mar 2014

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).

18 Mar 2014

Merck Millipore announces joint development agreement with Sysmex Corporation

Merck Millipore, the Life Science division of Merck, today announced a clinical research, licensing and joint development agreement with Sysmex Corporation of Japan.

From Sysmex America, Inc. 18 Mar 2014

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.

18 Mar 2014

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Dartmouth researchers have developed a novel and unique approach to treating Chronic Lymphocytic Leukemia (CLL), a form of blood cancer that often requires repeated chemotherapy treatments to which it grows resistant.

17 Mar 2014

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone™) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products.

17 Mar 2014

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

Derma Sciences' net sales increase 3% to $20.7 million in fourth quarter 2013

Derma Sciences, Inc., a tissue regeneration and burn care company focused on advanced wound care, today reported financial and operating results for the three months and year ended December 31, 2013.

14 Mar 2014

UC Davis MIND Institute named Intellectual and Developmental Disabilities Research Center

The UC Davis MIND Institute has been named an Intellectual and Developmental Disabilities Research Center, through a prestigious grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health - a distinction held by only a handful of neurodevelopmental centers nationwide committed to the diagnosis, prevention, treatment and amelioration of developmental disorders such as autism, fragile X syndrome and Down syndrome.

14 Mar 2014

Stem cell therapy may benefit patients with debilitating heart failure

Researchers want to know whether patients with debilitating heart failure can benefit by having their own stem cells injected into their ailing heart muscle.

14 Mar 2014

Researcher detects higher rate of seizures among children with autism who were fed soy formula

A University of Wisconsin-Madison researcher has detected a higher rate of seizures among children with autism who were fed infant formula containing soy protein rather than milk protein.

14 Mar 2014

Mindfulness-based meditation could lessen some symptoms of cancer in teens

Mindfulness-based meditation could lessen some symptoms associated with cancer in teens, according to the results of a clinical trial intervention led by researchers at the University of Montreal and its affiliated CHU Sainte-Justine children's hospital.

14 Mar 2014

Venaxis' APPY1 Test for appendicitis shows positive results in pivotal U.S. study

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study.

14 Mar 2014

SAGE Therapeutics announces completion of $38 million Series C financing

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the successful completion of a $38 million Series C financing. OrbiMed Advisors, LLC, EcoR1 Capital Management, Foresite Capital Management and two undisclosed blue chip public investment funds joined existing investors Third Rock Ventures and ARCH Venture Partners.

13 Mar 2014

Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the fourth quarter ended December 31, 2013, as well as recent business updates.

13 Mar 2014

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus and pazopanib in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have caused this exceptional response, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

13 Mar 2014

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Knopp Biosciences LLC today announced a second collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole.

13 Mar 2014

Researchers receive $3 million grant from NIH to study effects of asymmetric hearing loss

Researchers at Washington University School of Medicine in St. Louis have received a five-year, $3 million grant from the National Institutes of Health (NIH) to study the effects of asymmetric hearing loss in adults and children.

13 Mar 2014

Clinical Trial News and Research

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Merck Millipore announces joint development agreement with Sysmex Corporation

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Trovagene reports net loss of $1 million for fourth quarter 2013

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Derma Sciences' net sales increase 3% to $20.7 million in fourth quarter 2013

UC Davis MIND Institute named Intellectual and Developmental Disabilities Research Center

Stem cell therapy may benefit patients with debilitating heart failure

Researcher detects higher rate of seizures among children with autism who were fed soy formula

Mindfulness-based meditation could lessen some symptoms of cancer in teens

Venaxis' APPY1 Test for appendicitis shows positive results in pivotal U.S. study

SAGE Therapeutics announces completion of $38 million Series C financing

Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Researchers receive $3 million grant from NIH to study effects of asymmetric hearing loss

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer